STOCK TITAN

Miromatrix Medical Inc - MIRO STOCK NEWS

Welcome to our dedicated page for Miromatrix Medical news (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical stock.

Miromatrix Medical Inc. (MIRO) is revolutionizing organ transplantation through its proprietary bioengineering technology. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in addressing the global organ shortage crisis.

Access timely updates including quarterly financial results, clinical trial milestones, leadership developments, and strategic partnerships. Our curated collection features verified information about MIRO's perfusion platform advancements and industry recognition, such as their recent American Transplant Congress honors.

Key content categories include regulatory updates, research publications, executive team announcements, and manufacturing scale-up progress. Bookmark this page to stay informed about MIRO's pioneering work in creating transplant-ready human organs through their decellularization technology.

Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) successfully completes the tender offer to acquire Miromatrix Medical Inc. (Nasdaq: MIRO) for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to mirokidney™ by December 31, 2025. 22,876,102 shares of Miromatrix common stock were validly tendered, representing approximately 83% of the issued and outstanding shares. Merger Sub merged with and into Miromatrix, making it a wholly owned subsidiary of United Therapeutics. Shares of Miromatrix common stock ceased trading on Nasdaq, and United Therapeutics intends to cause such shares to be delisted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced the results of the tender offer by Merger Sub, a United Therapeutics subsidiary, to acquire all outstanding shares of Miromatrix for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s mirokidney™ product by December 31, 2025. The tender offer expired with shares representing more than a majority of the issued and outstanding Miromatrix common stock validly tendered and received. The merger is expected to be completed on December 13, 2023, with Miromatrix becoming a wholly owned subsidiary of United Therapeutics and its shares delisted from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Miromatrix Medical Inc. (Nasdaq: MIRO) reported third quarter 2023 financial results and announced a definitive merger agreement with United Therapeutics Corporation. The company's unrestricted cash and investments totaled $16.1 million, with an operating loss of $6.6 million for the third quarter. Miromatrix has agreed to be acquired by United Therapeutics for $3.25 per share in cash at closing, with an additional $1.75 per share upon the achievement of a clinical development milestone related to their mirokidney™ product by December 31, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) has announced its definitive agreement to acquire Miromatrix Medical Inc. (Nasdaq: MIRO), a life sciences company focused on bioengineered organs. The acquisition will expand United Therapeutics' organ manufacturing programs and address the shortage of transplantable organs. The purchase price is $3.25 per share in cash at closing, with an additional $1.75 per share upon achieving a clinical development milestone. The transaction is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Miromatrix Medical Inc. to present at ISODP Organ Donation Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
conferences
-
Rhea-AI Summary
Miromatrix Medical Inc. CEO to present at 2023 Cell & Gene Meeting on the Mesa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
Rhea-AI Summary
Miromatrix Medical Inc. to present at H.C. Wainwright Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary
Miromatrix Medical Inc. to present at ARM Tissue Engineering and Therapeutics Workshop on September 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.27%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences earnings
Miromatrix Medical Inc

Nasdaq:MIRO

MIRO Rankings

MIRO Stock Data

92.95M
20.65M
24.68%
22.04%
0.04%
Biotechnology
Healthcare
Link
United States
Eden Prairie